A new paper published by Cancer External Site describes approaches to pain measurement used in oncology clinical trials submitted to the U.S. Food and Drug Administration that are consistent with current FDA guidance principles. The purpose of the paper is to assist drug developers to include meaningful pain endpoints when designing cancer trials. "Measurement of pain and other symptoms is an essential part of cancer trials…
Breast density, as determined by mammography, is already known to be a strong and independent risk factor for breast cancer. …
In its earliest stages, breast cancer is confined to the breast and can be treated by surgically removing the cancer cells. As the disease progresses, breast cancer cells may spread to the lymph nodes and then to other areas of the body. "On its pathway to other places in the body, the first place breast cancer typically drains into before metastasizing is the lymph nodes," said Lilian Wang, M.D., assistant professor of radiology at Northwestern University/Feinberg School of Medicine in Chicago, Ill. "When breast cancer has spread into the lymph nodes, the patient is often treated both locally and systemically, with either hormone therapy, chemotherapy, trastuzumab or some combination of these therapies." Historically, healthcare organizations, such as RSNA and the American Cancer Society (ACS), have recommended annual screening with mammography for women beginning at age 40. …
The new guideline aims to aid primary care physicians and specialists who treat immunocompromised patients (people with compromised immune systems, such as those with cancer, HIV infection and Crohn’s disease), and those who live with immunocompromised patients. "The guideline provides ‘one-stop shopping’ for clinicians caring for children and adults with compromised immune systems and includes recommendations and evidence for all vaccinations, from influenza to chicken pox," said Dr. Rubin…
The study, published online by the journal AIDS, was authored by Jennifer Smith, PhD, MPH, research associate professor with the Gillings School of Global Public Health and member of the UNC Lineberger Comprehensive Cancer Center, and Anne Rositch, PHD, MSPH, assistant professor with the University of Maryland School of Medicine. "These data from Kenya add to a mounting evidence showing a higher risk of HIV acquisition among individuals with genital HPV infections," said Smith. Men in the study with at least one occurrence of HPV infection faced double the risk of acquiring HIV, and those with three or more HPV infections had more than three times the risk of developing HIV. This pattern was consistent in both circumcised and uncircumcised men…
In a study published online by Applied Physics Letters, a multidisciplinary team led by Physics Professor Otto Zhou, PhD; Radiation Oncology Associate Professor X. Sha Chang, PhD; and Physics Professor Jianping Lu, PhD, built a device using carbon nanotube-based x-ray source array technology developed at UNC that can generate microbeam radiation with similar characteristics as the beams generated by synchrotron radiation. Researchers from Applied Sciences and Radiology at UNC also participated in this study. Zhou, a member of the UNC Lineberger Comprehensive Cancer Center, points to several studies that have shown that microbeam radiation destroyed tumors and increased survival by as much as a factor of ten in brain tumor bearing animals treated with the technique. …
Working with local hospitals across North Carolina, UNC researchers led by Ronald Chen, MD, MPH, assistant professor of Radiation Oncology in the UNC School of Medicine, and Paul Godley, MD, PhD, Professor in the Division of Hematology/Oncology — both members of the UNC Lineberger Comprehensive Cancer Center — surveyed patients about their decision-making process after a prostate cancer diagnosis. "Prostate cancer is a unique disease where there are multiple treatment options, ranging from active surveillance to surgical treatments to radiation treatments…
Postmenopausal women with breast cancer whose treatment generally includes an aromatase inhibitor, or AI, often experience joint pain or stiffness known as AI-associated arthralgia. An estimated 20 to 32 percent of these women stop taking their AI due to this side effect. Researchers at the University of North Carolina at Chapel Hill conducted a pilot study to assess the potential positive effects of physical activity on joint pain and stiffness in these patients, as a potential alternative or adjunctive approach to arthralgia management that would enable them to continue their cancer therapy while living as pain- free as possible. "We were interested in seeing if a physical activity program that is evidence-based for reducing joint pain, stiffness and fatigue in adults with arthritis might have similar benefits for women experiencing AI- associated arthralgia," says Kirsten A…
Transitional cell carcinoma (TCC) is the most common type of bladder cancer diagnosed, accounting for 90% of all bladder malignancies in North America, South America, Europe, and Asia. It’s reported that there were an estimated 386,300 new bladder cancer cases and 150,200 deaths in 2008 alone. And the number was up to 170,000 deaths in 2010…
The new drug is set to become a reference in advanced pancreatic cancer treatment A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now. The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. …